Sumary of Icosapent ethyl provides ‘consistent benefit’ in patients with, without prior PAD:
- Presentation RF181. Presented at: American Heart Association Scientific Sessions;
- Back to Healio New analyses from the REDUCE-IT study show icosapent ethyl significantly reduced total primary CV endpoints by 32% in patients with prior peripheral artery disease, suggesting substantial benefit for a high-risk population.
- The data were presented at the American Heart Association Scientific Sessions.
- data from the REDUCE-IT trial show participants with a baseline history of PAD were much more likely to experience first and total primary endpoints over 5 years — a combination of CV death, MI, stroke, coronary revascularization and unstable angina — vs.
- Bhatt “If you look at risk for total events among the patients with peripheral artery disease in REDUCE-IT, it is actually rather staggering, 98.2%,” Cardiology Today Intervention Section Editor Deepak L.
- Bhatt, MD, MPH, executive director of interventional cardiology programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, said in an interview.
- ” As Healio previously reported, the main REDUCE-IT findings demonstrated icosapent ethyl (Vascepa, Amarin), a pharmaceutical-grade omega-3 fatty acid, was superior to placebo for reducing risk for ischemic events in patients with elevated triglycerides at high CV risk despite statin therapy.
- Patients were assigned icosapent ethyl 2 g twice daily or placebo and followed for a median of 4.9 years.